Our immunotherapy, currently in clinical trials, works to boost the ability of the body's own cancer-fighting cells to search and destroy cancerous tumors.

Bria-IMT™ and Bria-OTS™ are two promising drugs under development in our fight against breast cancer.Bria-IMT™ has shown remarkable results in clinical trials.  

Learn More
BriaCell’s Patented Immunotherapy


Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors.

We believe that Bria-IMT™

induces an antitumor response both indirectly (i.e. by providing the tumor antigens for the immune system to recognize) and directly by stimulating the immune system (i.e. further activating T-cells) which boosts the response

Learn More
Off-The-Shelf Personalized Immunotherapy


Supported by the data, “Matching Hypothesis” resulted in BriaCell’s “OTS” strategy

Introducing Bria-OTS™

  • We believe our treatment is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type
  • We are engineering 15 unique HLA types (molecules), collectively referred to as Bria-OTS™, allowing for what we believe will be matching and treatment of over 99% of patients with advanced breast cancer
  • Bria-OTS™ involves a simple saliva test to determine the HLA-type of each patient
  • Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation
  • Similar cell lines in development for prostate cancer, lung cancer, and melanoma
  • Preclinical models for prostate cancer, lung cancer, and melanoma are in development under Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (USA).
Learn More
briacell logo
    BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW;TSXV: BCT ) is a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors
  • Our lead drug candidate is Bria-IMT™. Our clinical program targetsthird-line advanced breast cancer which causes over 40,000 deaths per year in the U.S. alone.
    • 35 patients have been dosed to-date with robust responses seen in predictable sub-groups of patients → Our Phase I/IIa safety & efficacy show similar or superior results to those of other advanced or approved drugs for breast cancer when they were at similar stages of clinical development
  • Incyte Corporation (Nasdaq: INCY) → BriaCell has established a corporate collaboration and supply agreement with Incyte
    • This is a non-exclusive clinical trial collaboration to evaluate the effects of combination therapies
    • Bria-IMT™ + immune checkpoint inhibitors (Phase I/IIa)
      1. Bria-IMT™ + pembrolizumab (KEYTRUDA®) was initially evaluated in 11 patients → this study then transitioned to combinations with Incyte’s immune checkpoint inhibitors
      2. Bria-IMT™ + Incyte’s selected compounds are being investigated under the corporate collaboration and supply agreement
  • BriaCell is driving toward a Registration Study with initiation of the study expected in 2022 → Bria-IMT™ combined with immune checkpoint inhibitor(s)
  • Bria-OTS™: BriaCell is developing an “Off-The-Shelf Personalized” immunotherapy based on patient’s HLA-type
    • HLA molecules start immune responses but vary in the population
    • BriaCell’s preliminary data suggests that patients who match Bria-IMT™ at one or more HLA “types” are more likely to have clinical benefit.
    • This has led to the development of Bria-OTS™, where the cells have been genetically engineered to match the HLA type of more different patients.
    • BriaCell is extending this technology to other types of cancer (prostate cancer, lung cancer and melanoma).
    • This technology is being evaluated in a Collaborative Research and DevelopmentAgreement with the National Cancer Institute (part of NIH)
  • CEO Dr. William Williams has been involved in 11 prior drug approvals